Conv. Plasma
Nigella Sativa

All aspirin studies
Meta analysis
study COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 13% Improvement Relative Risk Aspirin for COVID-19  Chow et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? Retrospective 112,070 patients in the USA Lower mortality with aspirin (p=0.00004) Chow et al., JAMA Network Open, March 2022 Favors aspirin Favors control

Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19

Chow et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.3890
Mar 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 112,269 hospitalized COVID-19 patients in the USA, showing lower mortality with aspirin treatment.
risk of death, 13.5% lower, RR 0.87, p < 0.001, treatment 1,410 of 13,795 (10.2%), control 11,577 of 98,275 (11.8%), NNT 64, adjusted per study, odds ratio converted to relative risk, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chow et al., 24 Mar 2022, retrospective, USA, peer-reviewed, median age 63.0, 89 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
MD Jonathan H Chow, PhD Ali Rahnavard, MD, MSc Mardi Gomberg-Maitland, MS Ranojoy Chatterjee, MS Pranay Patodi, MD David P Yamane, MD Andrea R Levine, MD Danielle Davison, MD Katrina Hawkins, MD Amanda M Jackson, MD Megan T Quintana, MD Allison S Lankford, MD Ryan J Keneally, MD Mustafa Al-Mashat, MD Daniel Fisher, MD Jeffrey Williams, MD, MBA Jeffrey S Berger, MD, MPH Michael A Mazzeffi, PhD Keith A Crandall, Ivy Benjenk, Benjamin Amor, Christopher Austin, Tellen Bennett, Mark Bissell, Samuel Bozzette, Katie Bradwell, Carolyn Bramante, Yooree Chae, Christopher Chute, Marshall Clark, Conor Cook, Mariam Deacy, Alexandra Dest, Racquel Dietz, Thomas Dillon, David Eichmann, Patricia Francis, Rafel Fuentes, Davera Gabriel, Nicole Garbarini, Kenneth Gersing, Andrew Girvin, Alexis Graves, Justin Guinney, Melissa Haendel, Jeremy Harper, Wenndy Hernandez, Stephanie Hong, Warren Kibbe, Farrukh Koraishy, Kristin Kostka, Michael Kurilla, Adam Lee, Harold Lehmann, Hongfang Liu, Amin Manna, Federico Mariona, Julie Mcmurry, Sam Michael, Robert Miller, Richard Moffitt, Michele Morris, Andrew Neumann, Shawn O'neil, Matvey Palchuk, Philip Payne, Emily Pfaff, Nabeel Qureshi, Peter Robinson, Joni Rutter, Joel Saltz, Mary Saltz, Amit Saha, Usman Sheikh, Heidi Spratt, Justin Starren, Christine Suver, Meredity Temple-O'connor, Satyanarayana Vedula, Andrea Volz, Anita Walden, Kellie Walters, Adam Wilcox, Andew Williams, Chunlei Wu, Elizabeth Zampino, Ziaohan Zhang, Richard Zhu
JAMA Network Open, doi:10.1001/jamanetworkopen.2022.3890
IMPORTANCE Prior observational studies suggest that aspirin use may be associated with reduced mortality in high-risk hospitalized patients with COVID-19, but aspirin's efficacy in patients with moderate COVID-19 is not well studied. OBJECTIVE To assess whether early aspirin use is associated with lower odds of in-hospital mortality in patients with moderate COVID-19.
Author Contributions: Drs Chow and Crandall had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Mazzeffi and Crandall, as co-senior authors, contributed equally to the manuscript. Concept and design Conflict of Interest Disclosures: Dr Chow reported serving on the speaker's bureau for La Jolla Pharmaceutical Company outside the submitted work. Dr Gomberg-Maitland reported receiving honoraria from Medscape and serving as a consultant and member of the steering committees for Acceleron/Merck, Bayer, Janssen, and United Therapeutics outside the submitted work. Dr Mazzeffi reported receiving consulting fees from Hemosonics outside the submitted work. Dr Crandall reported receiving grants from the National Institutes of Health (NIH) and the National Science Foundation during the conduct of the study. No other disclosures were reported. Funding/Support: The analyses described in this publication were conducted with data or tools accessed through the National Center for Advancing Translational Sciences (NCATS) N3C Data Enclave and supported by grant U24 TR002306 from the NCATS. This study was also partially supported by grants NSF DEB-2028280 and DEB-2109688 from the National Science Foundation (Drs Rahnavard and Crandall) and 03UL1TR001876-05S1 from the NIH/NCATS (Dr Crandall), as well as an award from the George Washington University Office of the Vice President for Research (Dr..
Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat Med, doi:10.1002/sim.6607
Bowman, Mafham, Wallendszus, ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus, N Engl J Med, doi:10.1056/NEJMoa1804988
Chow, Khanna, Kethireddy, Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019, Anesth Analg, doi:10.1213/ANE.0000000000005292
Chow, Yin, Yamane, Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: a propensity score-matched analysis, J Thromb Haemost, doi:10.1111/jth.15517
Connors, Brooks, Sciurba, Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial, JAMA, doi:
Dong, Zhang, Zeng, Li, Subgroup balancing propensity score, Stat Methods Med Res, doi:10.1177/0962280219870836
Faraone, Interpreting estimates of treatment effects: implications for managed care, P T
Flower, The development of COX2 inhibitors, Nat Rev Drug Discov, doi:10.1038/nrd1034
Gaziano, Brotons, Coppolecchia, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial, Lancet, doi:10.1016/S0140-6736(18)31924-X
Guan, Ni, Hu, China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Haendel, Chute, Bennett, N3C Consortium. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment, J Am Med Inform Assoc, doi:10.1093/jamia/ocaa196
Hernan, Robins, Causal Inference: What If
Hernán, Robins, Using big data to emulate a target trial when a randomized trial is not available, Am J Epidemiol, doi:10.1093/aje/kwv254
Hernán, Sauer, Hernández-Díaz, Platt, Shrier, Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses, J Clin Epidemiol, doi:10.1016/j.jclinepi.2016.04.014
Ikeda, Shimada, Teramoto, Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial, JAMA, doi:
Liang, Liang, Ou, Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19, JAMA Intern Med, doi:
Lumley, Survey: analysis of complex survey samples
Mcneil, Wolfe, Woods, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly, N Engl J Med, doi:10.1056/NEJMoa1805819
Meizlish, Goshua, Liu, Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis, Am J Hematol, doi:10.1002/ajh.26102
Meizlish, Goshua, Liu, Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis, Am J, doi:10.1002/ajh.26102
Osborne, Veigulis, Arreola, Mahajan, Röösli et al., Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration, PLoS One, doi:10.1371/journal.pone.0246825
Pfaff, Girvin, Gabriel, Synergies between centralized and federated approaches to data quality: a report from the national COVID cohort collaborative, J Am Med Inform Assoc, doi:10.1093/jamia/ocab217
Ritchie, Mathieu, Rodés-Guirao, Coronavirus pandemic (COVID-19)
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med, doi:10.1007/s00134-020-05991-x
Schulte, Mascha, Propensity score methods: theory and practice for anesthesia research, Anesth Analg, doi:10.1213/ANE.0000000000002920
Van Der Wal, Geskus, Ipw: an R package for inverse probability weighting, J Stat Softw, doi:10.18637/jss.v043.i13
Warner, Nylander, Whatling, Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy, Br J Clin Pharmacol, doi:10.1111/j.1365-2125.2011.03943.x
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop